PDL BioPharma, Inc. EV/Operating CF

EV/Operating CF of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/Operating CF of PDL BioPharma, Inc. is -7.5 (as of December 30, 2019)
  • EV/Operating CF for the quarter ending June 29, 2020 was -2.49 (a -26.75% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -53.56%
  • Annual EV/Operating CF for 2019 was -7.5 (a -34.0% decrease from previous year)
  • Annual EV/Operating CF for 2018 was -11.36 (a -1575.19% decrease from previous year)
  • Annual EV/Operating CF for 2017 was 0.77 (a -77.97% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of PDL BioPharma, Inc.

Most recent EV/Operating CFof PDLI including historical data for past 10 years.

Interactive Chart of EV/Operating CF of PDL BioPharma, Inc.

PDL BioPharma, Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -2.49 -3.39
2019 -7.5 -5.35 7.65 -109.05 -7.5
2018 -11.36 -3.02 -1.95 -8.29 -11.36
2017 0.77 1.53 0.92 1.36 0.77
2016 3.5 3.81 2.19 1.5 3.5
2015 1.95 2.91 3.43 3.39 1.95
2014 4.11 4.17 6.34 4.17 4.11
2013 4.55 3.56 3.79 4.57 4.55
2012 5.29 6.01 4.96 5.07 5.29
2011 5.7 5.79 6.42 6.19 5.7
2010 0.0 0.0 0.0 0.0

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.